Broadpoint Upgrades Pharmacopeia (PCOP) to Strong Buy
More News related to PCOP
- Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes
- Pharmacopeia (PCOP) Receives $500K Milestone Payment from GlaxoSmithKline
- Pharmacopeia and GlaxoSmithKline Collaboration Identifies a New Lead Compound
- Pharmacopeia (PCOP) to Cut 15% of Workforce
- Pharmacopeia Advances Strategic Plan to Focus Resources on Development and Later-Stage Discovery Programs
Broadpoint Capital upgrades Pharmacopeia (Nasdaq: PCOP) from Buy to Strong Buy.
Pharmacopeia, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to address significant medical needs.
Related Categories
UpgradesStocks Mentioned
-0.12Related Entities
Sign up for StreetInsider Free!
Recieve full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
